None listed
Conditions
Brief summary
This study is investigating the ability of the SeedTracker monitoring system to improve the accuracy of radiotherapy treatment delivered to the prostate, and any resultant changes in patient quality of life during and after radiotherapy. Who is it for? You may be eligible for this study if you are a prostate cancer patient receiving definitive radiotherapy to the prostate with current treatment protocol used within Liverpool and Macarthur cancer therapy centres. Study details The SeedTracker system will detect the position of radiopaque markers implanted in patients during pre-treatment position verification via monoscopic x-ray images acquired in real-time during treatment delivery. Radiation oncologists, Radiation Therapists and Physicists will use this data to monitor treatment margins accordingly throughout treatment, whilst monitoring the actual dose of radiation delivered. Participants will also be asked to complete quality of life questionnaires monitoring their bowel, urinary and sexual function during treatment and up to 5 years after completion of treatment. The researchers hope this trial will result in better outcomes for prostate cancer patients and lower side effects.
Interventions
SeedTracker is a real-time position monitoring tool, developed in South Western Sydney Area Health Service to enable real-time position monitoring in Elekta linear accelerators. The majority of prostate cancer patients undergoing radiotherapy have the radiopaque markers implanted in the prostate for pre-treatment position verification. The SeedTracker system monitors the prostate position during the treatment delivery in real-time by detecting the position of the radiopaque markers via monoscopi
SeedTracker is a real-time position monitoring tool, developed in South Western Sydney Area Health Service to enable real-time position monitoring in Elekta linear accelerators. The majority of prostate cancer patients undergoing radiotherapy have the radiopaque markers implanted in the prostate for pre-treatment position verification. The SeedTracker system monitors the prostate position during the treatment delivery in real-time by detecting the position of the radiopaque markers via monoscopic x-ray images acquired during treatment delivery. Treating Radiation Therapists will use Seedtracker in conjunction with the Linear Accelerators to monitor the patient during radiotherapy treatment delivery. This process will also involve the support of Physicists and Radiation Oncologists. This will be delivered daily throughout the prescribed treatment course (20 or 39 days) at the participating hospitals. The treating Radiation Therapists will use Seedtracker to determine the position of the patient's prostate during radiotherapy treatment. If the prostate movement exceeds the set tolerance of 3mm from the planned position, the treatment will be paused and the patient will be realigned to the planned position and treatment will then continue. Study participants will be required to complete some questionnaires at various timepoints throughout their radiotherapy treatment and at follow up visits with the Radiation Oncologist. It is estimated that these questionnaires will take about 5 minutes to complete. This study will analyze the collected data to provide insight into treatment margins, treatment accuracy and doses to nearby critical structures (bladder and rectum). This study will also assess changes in patient's quality of life during and after radiotherapy treatment using Seedtracker.
Sponsors
South Western Sydney Local Health District
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Prostate cancer patients that receive radiotherapy treatment for prostate with current treatment protocol used within Liverpool and Macarthur cancer therapy centres. 2. Patients implanted with three prostate radio opaque markers 3. Patients receiving definitive radiotherapy to the prostate
Exclusion criteria
Patients with hip prosthesis
Outcome results
None listed